Drug

Acyclovir Sodium

73 flagged reaction(s) · 1,737 total co-reports · max PRR 83.3

Important: Reactions below are the flagged terms from this drug’s FAERS report history (min. 3 co-reports per term) — PRR/ROR indicate disproportionality in spontaneous reporting, not causation. Data from FDA FAERS via openFDA. Last recalculated: 2026-09-14.

	Reaction	Co-reports (a)	PRR	ROR	Signal
1	Full Blood Count Abnormal	52	83.3	86.9	signal
2	Carpal Tunnel Syndrome	65	78.2	82.4	signal
3	Blood Test Abnormal	63	75.8	79.8	signal
4	Sleep Disorder Due To A General Medical Condition	71	74.1	78.6	signal
5	Nephropathy	36	64.7	66.6	signal
6	Sleep Apnoea Syndrome	61	53.8	56.5	signal
7	Fibromyalgia	64	44.4	46.8	signal
8	Hypothyroidism	67	35.5	37.4	signal
9	Loss Of Personal Independence In Daily Activities	65	23.0	24.2	signal
10	Renal Disorder	62	22.4	23.5	signal
11	Haematotoxicity	12	21.8	22.0	signal
12	Cytomegalovirus Infection	20	20.2	20.6	signal
13	Haemorrhage Intracranial	17	19.1	19.3	signal
14	Wheezing	62	17.6	18.5	signal
15	Therapeutic Product Effect Incomplete	73	17.4	18.4	signal
16	Burning Sensation	72	17.3	18.3	signal
17	Lymphocyte Count Decreased	17	16.2	16.4	signal
18	Mucosal Inflammation	25	16.1	16.5	signal
19	Clostridium Difficile Colitis	10	15.8	16.0	signal
20	Gastrooesophageal Reflux Disease	69	14.5	15.3	signal
21	Nephropathy Toxic	9	13.6	13.7	signal
22	Multi-organ Failure	14	13.4	13.6	signal
23	Bacteraemia	9	12.9	13.0	signal
24	Glomerular Filtration Rate Decreased	9	12.5	12.6	signal
25	Cytokine Release Syndrome	14	12.4	12.5	signal
26	Renal Failure Acute	31	12.1	12.4	signal
27	Multiple Organ Dysfunction Syndrome	20	12.1	12.2	signal
28	Cardiac Disorder	65	11.6	12.2	signal
29	Asthma	75	11.3	11.9	signal
30	Cardiomegaly	8	10.8	10.9	signal
31	Gastric Ulcer	12	10.6	10.7	signal
32	Myoclonus	7	9.9	9.9	signal
33	Febrile Neutropenia	38	9.7	9.9	signal
34	Oral Herpes	11	9.5	9.6	signal
35	Blood Lactate Dehydrogenase Increased	9	9.5	9.6	signal
36	Muscle Atrophy	7	9.4	9.4	signal
37	Liver Function Test Abnormal	16	9.2	9.3	signal
38	Intentional Product Use Issue	48	9.2	9.5	signal
39	Grand Mal Convulsion	5	9.0	9.0	signal
40	Platelet Count Decreased	56	8.8	9.2	signal
41	Plasma Cell Myeloma	20	8.6	8.7	signal
42	Brain Oedema	6	8.0	8.0	signal
43	Neurotoxicity	8	7.7	7.8	signal
44	Adverse Event	39	7.1	7.3	signal
45	Herpes Zoster	24	7.0	7.1	signal
46	Hepatic Cytolysis	5	6.9	6.9	signal
47	Initial Insomnia	4	6.6	6.6	signal
48	Economic Problem	6	6.5	6.6	signal
49	Acute Myeloid Leukaemia	6	6.5	6.5	signal
50	Skeletal Injury	4	6.4	6.4	signal
51	Anhedonia	10	6.4	6.4	signal
52	Tooth Fracture	4	6.1	6.1	signal
53	Drug Toxicity	5	6.1	6.1	signal
54	Neutropenia	46	5.7	5.9	signal
55	Synovitis	6	5.6	5.6	signal
56	Toxic Epidermal Necrolysis	5	5.6	5.6	signal
57	Drug Exposure During Pregnancy	11	5.4	5.4	signal
58	Leukaemia	3	5.4	5.4	signal
59	Hallucination, Auditory	5	5.3	5.3	signal
60	Thrombotic Microangiopathy	3	5.2	5.2	signal
61	Bone Marrow Failure	6	4.9	5.0	signal
62	Poor Venous Access	3	4.9	4.9	signal
63	Hepatitis C	3	4.1	4.1	signal
64	Muscle Spasticity	3	4.1	4.1	signal
65	Convulsion	14	4.1	4.1	signal
66	Osteonecrosis	8	4.1	4.1	signal
67	Tooth Loss	5	4.0	4.0	signal
68	Anorexia	3	3.9	3.9	no signal
69	Bone Density Decreased	7	3.7	3.7	signal
70	Palmar-plantar Erythrodysaesthesia Syndrome	5	3.6	3.6	signal
71	Serotonin Syndrome	4	3.5	3.5	signal
72	Myelosuppression	7	3.5	3.5	signal
73	Bone Loss	3	3.3	3.3	no signal